Evidence map›Paper›PMID 34878955›Full record

Observational studyInfectious diseases (London, England)2022

Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.

Oskar Ljungquist, Maria Lundgren, Elena Iliachenko, Fredrik Månsson, Blenda Böttiger, Mona Landin-Olsson, Christian Wikén, Ebba Rosendal, Anna K Överby, Byström J Wigren and 5 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Infectious diseases (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Oskar LjungquistDepartment of Translational Medicine, Clinical Infection Medicine, Faculty of Medicine, Lund University, Malmö, Sweden.
Maria LundgrenDepartment of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.
Elena IliachenkoDepartment of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.
Fredrik MånssonDepartment of Translational Medicine, Clinical Infection Medicine, Faculty of Medicine, Lund University, Malmö, Sweden.
Blenda BöttigerDepartment of Clinical Microbiology, University and Regional Laboratories, Lund, Sweden.
Mona Landin-OlssonSkåne University Hospital, Malmö, Sweden.
Christian WikénSkåne University Hospital, Malmö, Sweden.
Ebba RosendalDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Anna K ÖverbyDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Byström J WigrenDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Mattias N E ForsellDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Jens Kjeldsen-KraghDepartment of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.
Magnus RasmussenSkåne University Hospital, Malmö, Sweden.ORCID 0000-0003-1588-5473
Fredrik KahnSkåne University Hospital, Malmö, Sweden.ORCID 0000-0001-5566-6350
Karin HolmSkåne University Hospital, Malmö, Sweden.ORCID 0000-0002-8289-5949
Lund University · SEUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunosuppressed patients are particularly vulnerable to severe infection from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia and symptom duration. In this study we describe clinical and virological treatment outcomes in a heterogeneous group of patients with severe immunosuppression due to various causes suffering from COVID-19 infection, who were all treated with convalescent plasma (CCP) along with standard treatment.

methodsWe performed an observational, retrospective case series between May 2020 to March 2021 at three sites in Skåne, Sweden, with a population of nearly 1.4 million people. All patients hospitalized for COVID-19 who received CCP with the indication severe immunosuppression as defined by the treating physician were included in the study (

resultsIn total, 28 severely immunocompromised patients, half of which previously had been treated with rituximab, who had received in-hospital convalescent plasma treatment of COVID-19 were identified. One week after CCP treatment, 13 of 28 (46%) patients had improved clinically defined as a decrease of at least one point at the WHO-scale. Three patients had increased score points of whom two had died. For 12 patients, the WHO-scale was unchanged.

conclusionAs one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression, this study adds descriptive data. The study design prohibits conclusions on safety and efficacy, and the results should be interpreted with caution. Prospective, randomized trials are needed to investigate this further.

Indexed as

COVID-19Immunization, PassiveImmunocompromised HostCOVID-19 SerotherapyHumansProspective StudiesRetrospective StudiesSARS-CoV-2SwedenAntibodiesconvalescent plasmaCOVID-19immunosuppressionlymphomapandemicPCRrituximabSARS-CoV-2

Identifiers

PMID34878955
PMCPMC8726003
OpenAlexW4200179399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.